Confirmed
One controlled phase 3 trial met its main goal, and alemtuzumab is approved for this use.
Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing MS
relapsing MS · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 13
- Running now
- 1
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 1174
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 12
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2007 · Compared with interferon beta-1a · MSFT-NCT00548405
Other linked trials: 12
These linked trials do not set the status.
- Magnify MS ExtensionNo result found
Phase 4 · 2021 · Not randomised
- CLARIFY MS ExtensionNo result found
Phase 4 · 2021 · Not randomised
- CLASSIC-MSNo result found
Phase 4 · 2019 · Not randomised
- DELIVER-MSOngoing
Phase 4 · 2019 · Not randomised
- ALAIN01Result in a paper, not read yet
Phase 4 · 2015 · Not randomised
- CAMA-2No result found
Phase 3 · 2011 · Not randomised
- CARE-MS Extension StudyNo result found
Phase 3 · 2009 · Not randomised
- CARE-MS IMissed main goal
Phase 3 · 2007 · Compared with interferon beta-1a
- COASTStopped, other reason
Phase 2 · 2021 · Compared with alemtuzumab, ocrelizumab
- High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyNo result found
Phase 2 · 2006 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Confirmed
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in early MS (CIS or RIS)
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in primary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing and progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in secondary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error